Exonate will be represented at the following upcoming meetings:
Ausbio Conference 2016 24-26th October, Melbourne
EVER Conference 2016, 5-8th October, Nice
Exonate to present at EVER 2016
Exonate will be attending the European Association for Vision and Eye Research (EVER) 2016 Congress 5th– 8th October 2016. Dr Jennifer Batson will present Exonate’s research into development of novel small molecule inhibitors of SRPK1 with improved scleral permeability properties for eye drop drug delivery. Delivery of sufficient drug levels to the back of the eye is a common challenge for eye drop administration. Exonate will present data supporting a novel approach its scientists have successfully developed to tackle this problem using rational medicinal chemistry and experimental models of ocular permeability.
Exonate’s team are available for meetings whilst there and contact can be made via Louise Shave Louise.email@example.com
BARS conference 2016, September 22nd Holiday Inn, Birmingham Airport
This year at BARS Exonate’s founding director Professor David Bates (Professor of Oncology and Head of Cancer Biology, University of Nottingham) will be speaking at 2pm. Delegates are invited to listen to his presentation on Eye Drops for Retinal Diseases: Future or Fantasy?
RESI 10th conference 2016, September 13th Boston MA
Exonate’s Chairman Sunil Shah will this year be attending RESI in Boston. Sunil can be contacted through the RESI partnering system and will be available in Boston from 13th to 16th September.
SPLICING conference 2016, September 12-14th, Lisbon, Portugal
Exonate will be very well represented at the 1st International Conference on Splicing in Lisbon, Portugal 12-14th September. The team are presenting data on development of novel inhibitors of alternative splicing. Exonate’s scientific advisor Dr Jonathan Morris will be presenting his poster presentation on the development of Small Molecule Inhibitors of RNA Splicing Kinases and team member Zoe Blackley on the development of SRPK1 Inhibitors for use as Novel Analgesics.
Founding director Professor David Bates is a plenary speaker at the event and will be discussing the development of alternative splicing regulators as novel therapeutics. There will also be oral contributions from Exonate’s founding scientist Dr Lucy Donaldson. She will discuss inhibitors of alternative splicing as novel analgesics.
Dr Jenny Batson is an oral contributor. Her title, Novel SRPK1 inhibitors potently and selectively inhibit SRPK1-regulated VEGF-A alternative splicing with properties to control angiogenesis in vivo, will be discussed.
Exonate’s team members are available for meetings whilst there and contact can be made via Louise Shave. Louise.firstname.lastname@example.org.